Ipsc Derived Microglia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
iPSC-derived microglia are microglia generated from induced pluripotent stem cells (iPSCs), providing a human cellular model for studying microglial biology, neuroimmune interactions, and therapeutic drug screening. These cells offer significant advantages over immortalized cell lines and rodent primary microglia, enabling research into disease-specific microglial phenotypes and personalized medicine approaches.
iPSC-derived microglia recapitulate many key features of primary human microglia, including:
The most common approach involves:
An alternative approach uses transcription factor-mediated conversion:
Modern Good Manufacturing Practice (GMP)-compatible methods:
| Marker | Expression | Function |
|---|---|---|
| TMEM119 | High | Transmembrane protein, homeostatic marker |
| P2RY12 | High | Purinergic receptor, process motility |
| CX3CR1 | High | Fractalkine receptor, neuron-microglia signaling |
| CD11b (ITGAM) | High | Integrin, phagocytosis |
| CD45 (PTPRC) | Variable | Leukocyte common antigen |
| CD68 | Inducible | Phagocytosis marker |
| Iba1 (AIF1) | High | Calcium-binding protein |
| TREM2 | Variable | ing receptor on Trigger myeloid cells |
RNA-seq analyses show iPSC-microglia cluster with primary human microglia:
iPSC-microglia from AD patients reveal:
PD iPSC-microglia demonstrate:
ALS patient-derived microglia:
iPSC-microglia enable high-throughput screening:
Autologous iPSC-derived microglia transplantation:
iPSC-microglia in advanced culture models:
| System | Applications |
|---|---|
| Brain organoids | Development, disease modeling |
| Assembloids | Circuit formation, connectivity |
| Microfluidic chips | BBB modeling, drug transport |
| 3D scaffolds | Tissue engineering |
The study of Ipsc Derived Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Muffat J, Li Y, Omer A, et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med. 2016;22(11):1358-1367. PMID:27668937.
Douvaras P, Sun B, Wang M, et al. Directed differentiation of human pluripotent stem cells to microglia. Stem Cell Reports. 2017;8(6):1516-1524. PMID:28528711.
Haenseler W, Sansom SN, Buchrieser J, et al. A Next Generation Model for Human Microglia with Point Mutations. Cell Stem Cell. 2017;21(5):683-689. PMID:29100015.
Chen SW, Hung YS, Fuh JL, et al. Efficient generation of microglia-like cells from human iPSCs. Nat Neurosci. 2019;22(10):1701-1712. PMID:31451805.
Konttinen H, Gureviciene I, Oksanen M, et al. Human iPSC-derived microglia: A promising tool for understanding ALS pathogenesis. Stem Cell Res Ther. 2021;12(1):122. PMID:33557870.
Lin YT, Seo J, Gao F, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived microglia. Nat Neurosci. 2018;21(4):552-563. PMID:29556031.
McQuade A, Coburn M, Stathopoulos A, et al. Development and validation of humanized microglia in the mouse. Nat Neurosci. 2020;23(6):781-794. PMID:32341543.